April 19, 2022
Article
The oral PARP inhibitor is associated with increased PFS, regardless of BRCA mutational status.
February 15, 2022
Niraparib is associated with increased progression-free survival, regardless of the presence or absence of BRCA gene mutations.
February 11, 2022
The drug's novel molecular structure may result in fewer toxic adverse effects.
February 02, 2022
Darolutamide exerts its effects via competitive inhibition of androgen binding.